Showing 2111-2120 of 5771 results for "".
- Zeiss Announces 3 Million Eyes Treated With SMILEhttps://modernod.com/news/zeiss-announces-3-million-eyes-treated-with-smile/2477881/Zeiss Medical Technology announced a new milestone with more than 3 million treated eyes with SMILE in more than 1,000 clinics worldwide. SMILE, which became commercially available in the United States in 2017, is a minimally-invasive corneal refractive procedure performed by using the Vi
- ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Data Through ARVOhttps://modernod.com/news/proqr-announces-virtual-presentation-of-phase-1-2-sepofarsen-data-through-arvo/2479525/ProQR Therapeutics announced a virtual presentation of data from the company’s phase 1/2 trial of sepofarsen. The data will be shared via a video presentation through the Association for Research in Vision and Ophthalmology (ARVO). It is the first time this data, previously announced in a
- Phosphorus Announces FDA Approval Of At-Home Saliva Test For COVID-19https://modernod.com/news/phosphorus-announces-fda-approval-of-at-home-saliva-test-for-covid-19/2477868/Phosphorus announced today that the FDA granted the Emergency Use Authorization request for its saliva test for COVID-19 that features at-home sample collection. The test is available by ordering online, as well as through health care and employer partnerships aimed at safely resuming operations.
- Prevent Blindness to Host Ninth Annual Focus on Eye Health National Summit as an Online Virtual Eventhttps://modernod.com/news/prevent-blindness-to-host-ninth-annual-focus-on-eye-health-national-summit-as-an-online-virtual-event/2477861/Prevent Blindness will host the 9th annual Prevent Blindness Focus on Eye Health National Summit, on July 15, 2020, from 12-3 p.m. ET (a virtual exhibit hall will be open from 11 a.m.- 4 p.m. ET
- Adverum Biotechnologies Announces New INFINITY Phase 2 Trial for DME Drug Candidatehttps://modernod.com/news/adverum-biotechnologies-announces-new-infinity-phase-2-trial-for-dme-drug-candidate/2477842/Adverum Biotechnologies announced the initiation of INFINITY, a phase 2, multicenter, randomized, double-masked, active comparator-controlled trial to assess a single intravitreal (IVT) injection of ADVM-022 in patients with diabetic macular edema (DME). The company also reported financial resul
- Sonoma Pharmaceuticals Announces New CE Marking for Microdacyn60 Eye Carehttps://modernod.com/news/sonoma-pharmaceuticals-announces-new-ce-marking-for-microdacyn60-eye-care/2477833/Sonoma Pharmaceuticals has announced that it received a new CE Marking for its Microdacyn60 eye care based on Sonoma’s patented Microcyn Technology. The formulation, marketed in the United States as Acuicyn Antimicrobial Eyelid and Eyelash Hygiene solution, is a safe and efficac
- Bausch + Lomb Announces European Launch of a New Platform of Preloaded IOLs, LuxSmart and LuxGoodhttps://modernod.com/news/bausch-lomb-announces-the-launch-of-a-new-platform-of-preloaded-iols-luxsmart-and-luxgood/2477823/Bausch + Lomb announced the European launch of the company’s first presbyopia correcting IOL, LuxSmart, and its monofocal version, LuxGood. Both feature preloaded delivery systems and Pure Refractive Optics (PRO) Technology. LuxSmart and LuxGood comprise a hydrophobic material and repres
- Avellino Announces A.C.T.S. Program to Help Eye Care and Other Surgical Practices Protect Patients and Staff From COVID-19https://modernod.com/news/avellino-announces-a-c-t-s-program-to-help-eye-care-and-other-surgical-practices-protect-patients-and-staff-from-covid-19/2477792/Avellino announced the rollout of the new A.C.T.S. Program (Active Coronavirus Testing & Safety) designed to help ophthalmology and other elective surgery and procedure-oriented practices safely reopen and resume care while protecting patients and staff from COVID-19 virus transmission. <
- Samsung Bioepis Announces 24-Week Interim Results From a Phase 3 Trial of Ranibizumab Biosimilarhttps://modernod.com/news/samsung-bioepis-announces-24-week-interim-results-from-a-phase-3-trial-of-ranibizumab-biosimilar/2477785/Samsung Bioepis announced that the primary endpoints have been met in the randomized, double-masked, phase 3 trial comparing the efficacy, safety and immunogenicity of SB11, a ranibizumab biosimilar candidate, to reference ranibizumab in patients with wet age-related macular degeneration (AMD).</
- Sight Sciences Announces Positive Clinical Results From Trial Evaluating TearCare for the Treatment of Dry Eye Diseasehttps://modernod.com/news/sight-sciences-announces-positive-clinical-results-from-trial-evaluating-tearcare-for-the-treatment-of-dry-eye-disease/2477787/Sight Sciences announced new dry eye clinical data from a multicenter trial of TearCare, the first wearable eyelid technology for dry eye. Data from the study were presented at the American Society of Cataract Refractive Surgery (ASCRS) Virtual annual meeting by Jennifer Loh, MD, practicing ophth